Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
AxisBiotix is a life sciences company specializing in the development and commercialization of microbiome-based products designed to improve skin health. As a subsidiary of SkinBioTherapeutics plc, the company utilizes the proprietary SkinBiotix platform to create non-pharmaceutical solutions for chronic skin conditions. Its flagship product, AxisBiotix-Ps, is a clinically studied probiotic food supplement formulated to manage the symptoms of psoriasis by modulating the gut-skin axis. The company's business model focuses on direct-to-consumer sales and expanding its portfolio to address other dermatological concerns such as eczema and acne. By combining probiotic science with dermatological research, AxisBiotix aims to provide natural, effective alternatives to traditional topical treatments.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on AxisBiotix.